Tim Horn

Advocates from the Treatment Action Group (TAG) explain why results of clinical trials should be more transparent.

The passing of our cherished friend and comrade Spencer Cox on December 18, 2012 cut us deeply and painfully.

Dolutegravir, the once-daily integrase inhibitor that doesn’t require boosting, continues to leave a trail of encouraging news on its path to...

For uninsured HIV-positive people with low incomes, applying for free or discounted HIV meds just got a little bit easier.

Hypogonadism, or low T, is common in men with the virus and can cause problems like fatigue, depression and bone loss.

A group of plant chemicals is being eyed by Johns Hopkins University (JHU) researchers for its ability to protect brain function in people liv...

Is Selzentry (maraviroc) the next best pre-exposure prophylaxis, or PrEP, for HIV-negative individuals looking to avoid contracting the virus?

Formerly known as the Quad, the single-tablet regimen Stribild was approved in late August and landed on pharmacy shelves soon thereafter.

A group of HIV-positive French individuals—14 at last count—may be yet another piece of the cure puzzle.

HIV-positive people who experience a heart attack and require hospitalization are more likely to die, compared with those not living with the...

Patients were enthusiastic about open access to primary care provider visit notes.

At an inner city Baltimore HIV clinic serving a primarily poor and black population, the average life expectancy is now 73 years, according to...

Black women living with HIV and hepatitis C virus (HCV) are less likely to die of liver disease, compared with white and Latina women coinfect...

Most HIV-positive people who should be taking aspirin to prevent a heart attack or stroke are not doing so.

The Fair Pricing Coalition and other activists are taking Gilead Sciences to task for what they say is an exorbitant per-patient annual wholes...